Boehringer will look after the production of E. coli strains and manufacturing of tox and clinical stage material for multiple DARPin products.
Boehringer Ingelheim biopharmaceuticals corporate senior vice president Simon Sturge said, "This agreement reflects the strategy of Boehringer Ingelheim and its new brand Boehringer Ingelheim BioXcellence to be dedicated and committed to the development of highly innovative molecule platforms and projects."
Molecular Partners chief executive officer Christian Zahnd said, "Both monospecific and multispecific DARPins could be expressed intracellularely in E. coli as soluble proteins at high titers and were successfully purified to highest standards."